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OBJECTIVE — To assess the relative contribution of increased fasting and postload plasma
glucose concentrations to the incidence of type 2 diabetes in subjects with a normal 2-h plasma
glucose concentration.
RESEARCH DESIGN AND METHODS — A total of 3,450 subjects with 2-h plasma
glucose concentration 140 mg/dl at baseline were followed up in the San Antonio Heart Study
(SAHS) and the Botnia Study for 7–8 years. The incidence of type 2 diabetes at follow-up was
related to the fasting, 1-h, and 2-h plasma glucose concentrations.
RESULTS — In subjects with 2-h plasma glucose 140 mg/dl, the incidence of type 2 dia-
betes increased with increasing fasting plasma glucose (FPG) and 1-h and 2-h plasma glucose
concentrations. In a multivariate logistic analysis, after adjustment for all diabetes risk factors,
theFPGconcentrationwasastrongpredictoroftype2diabetesinboththeSAHSandtheBotnia
Study (P  0.0001). However, when the 1-h plasma glucose, but not 2-h plasma glucose,
concentration was added to the model, FPG concentration was no longer a signiﬁcant predictor
of type 2 diabetes in both studies (NS). When subjects were matched for the level of 1-h plasma
glucose concentration, the incidence of type 2 diabetes markedly increased with the increase in
1-h plasma glucose, but the increase in FPG was not associated with a signiﬁcant increase in the
incidence of type 2 diabetes.
CONCLUSIONS — An increase in postload glycemia in the normal range is associated with
an increase in the incidence of type 2 diabetes. After controlling for 1-h plasma glucose concen-
tration, the increase in FPG concentration is not associated with an increase in the incidence of
type 2 diabetes.
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I
mpaired fasting glucose (IFG) was in-
troduced in 1997 by the American Di-
abetes Association (ADA) (1), and,
analogous with impaired glucose toler-
ance (IGT), it was meant to represent an
intermediate stage in the transition from
normal glucose tolerance (NGT) to overt
type 2 diabetes. Both IFG and IGT indi-
cate an increased risk for future type 2
diabetes(2–4).Previously(5–7),wehave
shown that the 1-h plasma glucose con-
centration has better predictive power
than either fasting plasma glucose (FPG)
or2-hplasmaglucose,suggestingthatthe
1-h plasma glucose concentration may
have greater utility in identifying subjects
at increased risk for type 2 diabetes in
routine clinical practice.
Previous studies have reported that
IFG and IGT represent separate clinical
entities, which are characterized by dis-
tinct metabolic abnormalities (8–13).
Subjects with IGT manifest insulin resis-
tance in skeletal muscle (9–12) and im-
paired-cellfunction(bothearlyandlate
phases of insulin secretion) (10,14–16),
whereas subjects with IFG are character-
ized by increased hepatic insulin resis-
tance (9,16), impaired early insulin
response (12), and decreased non–
insulin-dependent glucose clearance
(15). Because of the prominent role of
progressive -cell failure in the develop-
ment of hyperglycemia (17), the impair-
ment in -cell function in subjects with
IGT represents a major pathogenic factor
for their increased risk for future type 2
diabetes. Although the increase in fasting
plasma glucose is associated with a de-
crease in ﬁrst-phase insulin secretion
(11–13,18), subjects with IFG have ro-
bust second-phase insulin secretion, and,
when related to their prevailing level of
insulin resistance, they have second-
phase insulin secretion comparable with
that of subjects with NGT (12,13). Thus,
impaired -cell function cannot fully ex-
plain the increased incidence of type 2
diabetes associated with the increase in
FPG concentration, e.g., in subjects with
isolated IFG.
Previously we have shown a strong
correlation between insulin resistance in
skeletal muscle and liver (16). Thus, a
strongcorrelationbetweenFPGandpost-
load plasma glucose concentrations is an-
ticipated. Therefore, we hypothesized
that the increased type 2 diabetes risk as-
sociated with the increase in FPG, at least
in part, is due to the increased postpran-
dial plasma glucose concentration associ-
ated with the increase in FPG and is not
duetotheincreaseinFPGperse.Theaim
of this study was to test this hypothesis.
RESEARCH DESIGN AND
METHODS— Subjects were partici-
pants in the San Antonio Heart Study
(SAHS) (19–21) and the Botnia Study
(22), who were free of diabetes at base-
line. The two studies are prospective lon-
gitudinal studies in which nondiabetic
subjects (Caucasian and Mexican Ameri-
canintheSAHSandCaucasianintheBot-
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for7–8years.Detaileddescriptionsofthe
Botnia Study and SAHS were published
previously (19–22). Only subjects with
2-h plasma glucose concentrations 140
mg/dlwereincludedinthisstudy.Table1
presents the baseline patient characteris-
tics. All subjects completed a 7- to 8-year
follow-up examination and had their dia-
betes outcome determined with a repeat
oral glucose tolerance test (OGTT).
During the baseline studies, data for
clinical and anthropometric parameters
(age, sex, BMI, and ethnicity) were col-
lected. Blood pressure and lipid proﬁle
were measured. In addition, all subjects
underwent a 75-g OGTT after a 12-h
overnight fast. Plasma glucose and serum
insulin concentrations were measured at
0,30,60,and120min.After7–8yearsof
follow-up (mean of 7.6 years in Botnia
Study participants and 7.2 years in the
SAHS participants), a repeat OGTT was
performed, and the diagnosis of diabetes
was based on ADA criteria: 2-h plasma
glucose 200 mg/dl or FPG 126 mg/dl (1).
Plasma glucose was measured by the glu-
cose oxidase method using a Beckman
glucose analyzer (Beckman Instruments,
Fullerton, CA) in both studies.
Data analysis and statistical
methods
To assess the contribution of FPG to the
risk of type 2 diabetes, a multivariate lo-
gistic model was constructed and in-
cluded the incidence of type 2 diabetes at
follow-up as the dependent variable and
FPG, age, sex, BMI, ethnicity, family his-
tory for type 2 diabetes, HDL cholesterol,
and systolic blood pressure as the inde-
pendentvariables.Toassesstheimpactof
postload plasma glucose concentration
on type 2 diabetes risk, the 1-h plasma
glucose or the 2-h plasma glucose con-
centration was added to the model.
To further assess the impact of 1-h
plasma glucose concentration compared
with FPG on the future risk of type 2 di-
abetes, we pooled the subjects from the
two studies, and subjects were divided
based on their FPG into two groups: 1)
NGT(FPG100mg/dl)and2)IFG(FPG
100–125 mg/dl). Subjects in each group
subsequently were divided into sub-
groupswithmatched1-hplasmaglucose.
The pooling of the subjects from the two
studies (rather than making the subdivi-
sion in each study separately) was per-
formedtoincreasethenumberofsubjects
in each subgroup. Because subjects re-
ceived similar tests at baseline and were
followed for a similar period of time,
pooling the subjects from the two studies
should not introduce a bias to the study.
To obtain subgroups with comparable
postload plasma glucose levels, subjects
with normal fasting glucose and IFG sub-
jects were divided into subgroups based
on their 1-h plasma glucose concentra-
tion (1-h plasma glucose 100, 100–
124, 125–149, 150–175, 175–200, and
200 mg/dl), and the incidence of type 2
diabetes in each group was related to the
1-h plasma glucose concentration. Inter-
estingly, none of the subjects with FPG
100 mg/dl had a 1-h plasma glucose
200 mg/dl. Thus, the subgroup with
FPG 100–125 mg/dl and 1-h plasma glu-
cose 200 mg/dl does not have a
matched group with FPG 100 mg/dl
and 1-h plasma glucose 200 mg/dl.
Variables are presented as means 
SD. The signiﬁcance of the mean differ-
ences was tested with ANOVA. Differ-
ences among categorical variables were
tested with the 
2 test. Statistical signiﬁ-
cance was considered at the level of P 
0.05. Statistical analysis was performed
with SPSS (version 17; SPSS, Chicago, IL).
RESULTS— The crude incidence rate
of type 2 diabetes over 7–8 years of fol-
low-up was greater in the SAHS than in
the Botnia Study (6.3 vs. 3.6%, respec-
tively, P  0.0005). In the SAHS, the
crude incidence of type 2 diabetes was
ethnicitydependent,withMexicanAmer-
icans having a greater incidence of type 2
diabetes than Caucasians (7.9 vs. 3.5%,
P  0.002).
In a multivariate logistic model that
included, in addition to FPG concentra-
tion, age, sex, BMI, family history of type
2 diabetes, ethnicity, HDL cholesterol,
and systolic blood pressure as indepen-
dent variables, only age, BMI, and ethnic-
ity were signiﬁcant predictors in the
SAHS, and age, BMI, and systolic blood
pressureweresigniﬁcantpredictorsinthe
Botnia Study (Table 2). FPG concentra-
tion was a strong predictor of type 2 dia-
betes in both studies (P  0.0001). To
assess whether the strong predictive
power of FPG is related to the increase in
FPG per se or to the strong correlation
between FPG and postload plasma glu-
cose concentration, we added 1-h plasma
glucose and 2-h plasma glucose concen-
tration to the logistic model. When the
1-h plasma glucose was added to the
model, only BMI and ethnicity remained
signiﬁcantpredictorsintheSAHSandage
and BMI in the Botnia Study (Table 2).
FPG no longer was a signiﬁcant predictor
in either study, whereas the 1-h plasma
glucose was the strongest predictor for
type 2 diabetes (P  0.0001). However,
when 2-h plasma glucose was added to
the model, it did not signiﬁcantly affect
the predictive power of FPG, age, BMI,
ethnicity,andsystolicbloodpressure(Ta-
ble 2).
To further examine the contribution
of FPG and 1-h plasma glucose to type 2
diabetesrisk,wecombinedsubjectsinthe
SAHS and Botnia Study and divided sub-
jects with IFG and normal fasting glucose
into subgroups matched in their 1-h
plasma glucose concentration. The 7- to
8-year incidence of type 2 diabetes in the
wholepopulationincreasedprogressively
with increasing FPG, 1-h plasma glucose,
and 2-h plasma glucose concentrations.
Whensubjectsweredividedinto10equal
deciles, the incidence of type 2 diabetes
markedly increased in deciles 9 and 10
compared with deciles 1–8 (8.1 vs. 3.9,
14.5 vs. 2.3, and 8.6 vs. 3.8% for FPG,
Table 1—Baseline patient characteristics in the SAHS and Botnia Study
SAHS Botnia Study P
n 1,390 2,060 0.0001
Age (years) 43  03 45  0.3 0.0001
Sex (% male) 56 52.9 0.0001
BMI 27.3  0.2 25.5  0.1 0.0001
Systolic blood pressure (mmHg) 117  0.4 126  0.4 0.0001
Diastolic blood pressure (mmHg) 71  0.3 94  0.2 0.0001
FPG (mg/dl) 85  0.3 99  0.2 0.0001
1-h plasma glucose (mg/dl) 125  1 133  0.5 0.0001
2-h plasma glucose (mg/dl) 96  0.6 104  0.5 0.0001
HDL (mg/dl) 47  0.4 54  0.6 0.0001
Triglycerides (mg/dl) 132  2 108  2 0.0001
Type 2 diabetes incidence (%) 6.33 3.64 0.0001
Fasting hyperglycemia and future diabetes risk
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cose, respectively; all P  0.0001).
To further assess the impact of 1-h
plasmaglucoseonthepredictivepowerof
FPG, we divided the subjects into two
groups based on FPG: 1) FPG 100
mg/dl and 2) FPG 100–125 mg/dl. To
control for the level of postload hypergly-
cemia, we divided the subjects in each
group into six subgroups with compara-
ble 1-h plasma glucose values. Figure 1
showsthatinsubjectswithIFGandNGT,
the incidence of type 2 diabetes rose pro-
gressively with the increase in 1-h plasma
glucose concentration. However, at any
given level of 1-h plasma glucose concen-
tration,theincidenceoftype2diabetesin
subjects with IFG was comparable to that
in subjects with NGT.
Previous studies have reported that
the decrease in ﬁrst-phase insulin secre-
tion begins at an FPG concentration well
within the normal range (90 mg/dl)
(18,23). To examine whether the in-
creased incidence of type 2 diabetes be-
gins at lower FPG concentrations, we
dividedsubjectswithNGTintothreesub-
groups (FPG 90, 90–100, and 100
mg/dl) and compared their incidence of
type 2 diabetes with that in subjects with
IFG.Subjectsinthesegroupswerefurther
subdivided into three groups based on
their 1-h plasma glucose concentration:
125, 125–150, and 150 mg/dl (Table
3). Again, at any given level of 1-h plasma
glucose concentration, the incidence of
type 2 diabetes was independent of the
FPG concentration and, in each group of
FPG values, it rose with increasing 1-h
plasma glucose concentration.
CONCLUSIONS— The major ﬁnd-
ing of the present study is that, after con-
trolling for the level of postload
hyperglycemia, e.g., 1-h plasma glucose
concentration, the increase in FPG con-
centration in subjects with NGT and IFG
is not associated with a signiﬁcant in-
crease in the incidence of type 2 diabetes
(Fig. 1, Table 3). When subjects were
matchedfortheir1-hplasmaglucosecon-
centration (Table 1), an increase in FPG
concentration from 90 up to 100–125
mg/dl (i.e., impaired fasting glucose) is
not associated with a signiﬁcant increase
in the incidence of type 2 diabetes. This
observation was consistent in subjects
with low postload hyperglycemia (e.g.,
1-hplasmaglucose125mg/dl)andalso
in subjects with a high level of postload
hyperglycemia (e.g., 1-h plasma glucose
150 mg/dl). Conversely, after we con-
trolled for other risk factors, the increase
in postload hyperglycemia (measured
with 1-h plasma glucose) was associated
withamarkedincreaseintheincidenceof
type 2 diabetes, independent of the level
of FPG concentration (Fig. 1, Table 3).
Our results indicate that an increase in
postloadhyperglycemia,intherangecon-
sideredtorepresentnormalglucosetoler-
ance(2-hplasmaglucose140mg/dl),is
the principal risk factor responsible for
theincreasedincidenceoftype2diabetes.
Insubjectswith2-hplasmaglucose140
mg/dl, an increase in FPG concentration
does not signiﬁcantly contribute to an in-
cidence of type 2 diabetes. For example,
subjects with FPG 90 mg/dl and 1-h
plasma glucose 150 mg/dl have an
13-fold elevated risk for developing di-
abetes compared with subjects with FPG
100–125 mg/dl and 1-h plasma glucose
125 mg/dl, despite comparable 2-h
plasma glucose concentrations (Table 3).
Previous epidemiological studies
have shown that subjects with isolated
IFG have a signiﬁcantly increased inci-
dence of type 2 diabetes compared with
that of individuals with NGT (2–4,8).
However, in these studies, the level of
postload hyperglycemia was not taken
Figure1—Seven-to8-yearincidenceoftype2
diabetes (T2DM) in subjects with normal fast-
ing glucose (FPG 100 mg/dl) and impaired
fasting glucose (FPG 100–125 mg/dl). Sub-
jects were divided into six groups according to
ﬁxed intervals of 1-h plasma glucose concen-
tration as follows: 100, 100–125, 125–150,
150–175, 175–200, and 200 mg/dl. The
mean 1-h plasma glucose concentration (n)i n
subjects with FPG 100 mg/dl was 85 (652),
113 (732), 139 (634), 165 (206), and 192
(187) mg/dl and in subjects with FPG 110
mg/dlwas91(104),114(224),140(333),165
(158), 193 (169), and 241 (51) mg/dl, respec-
tively. None of the subjects with FPG 100
mg/dl had a 1-h plasma glucose concentration
200 mg/dl.
Table 2—Multivariate logistic model for the future risk of type 2 diabetes as the dependent
variable and FPG, age, sex, BMI, ethnicity, family history for type 2 diabetes, blood pressure,
and HDL cholesterol as the independent variables (model 1)
SAHS Botnia Study
OR (95%CI) P OR (95% CI) P
Model 1
Age 1.03 (1.004–1.05) 0.01 1.04 (1.02–1.06) 0.001
BMI 1.1 (1.06–1.14) 0.0001 1.1 (1.04–1.18) 0.002
Ethnicity 0.53 (0.3–0.93 0.02 NA
Systolic blood pressure 1.01 (0.997–1.03) NS 1.02 (1.002–1.03) 0.02
FPG 1.06 (1.04–1.08) 0.0001 1.05 (1.02–1.08) 0.0001
Model 2
1-h plasma glucose 1.03 (1.02–1.04) 0.0001 1.02 (1.01–1.03) 0.0001
Age 1.02 (0.99–1.04) NS 1.04 (1.01–1.06) 0.004
BMI 1.08 (1.04–1.13) 0.0001 1.07 (1.006–1.14) 0.03
Ethnicity 0.46 (0.256–0.83) 0.01 NA
Systolic blood pressure 1.0 (0.98–1.02) NS 1.01 (0.99–1.03) NS
FPG 1.02 (0.99–1.05) NS 1.02 (0.99–1.06) NS
Model 3
2-h plasma glucose 1.02 (1.004–1.03) 0.007 1.04 (0.8–1.35) NS
Age 1.02 (1.001–1.05) 0.04 1.04 (1.015–1.06) 0.001
BMI 1.09 (1.05–1.13) 0.0001 1.09 (1.02–1.16) 0.01
Ethnicity 0.58 (0.316–0.985) 0.04 NA
Systolic blood pressure 1.0 (0.98–1.02) NS 1.02 (1.01–1.03) 0.02
FPG 1.05 (1.03–1.08) 0.0001 1.05 (1.02–1.08) 0.001
Data are ORs (95% CI) for the variables that were signiﬁcant predictors of type 2 diabetes risk. In model 2,
the 1-h plasma glucose concentration during the OGTT was added to model 1, and in model 3, the 2-h
plasma glucose concentration during the OGTT was added to the model.
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study, the incidence of type 2 diabetes in
subjects with IFG was signiﬁcantly
greater than that in subjects with NGT.
However, after controlling for the level of
postload hyperglycemia, measured with
the1-hplasmaglucoseconcentration,the
increase in FPG concentration was not
signiﬁcantly associated with an increased
incidence of type 2 diabetes. Thus, our
results indicate that the increased inci-
dence of type 2 diabetes in subjects with
IFG compared with those with NGT is
due to inclusion of subjects with postload
hyperglycemia, i.e., subjects with 1-h
plasma glucose 150 mg/dl, and is not
due to the increase in FPG per se. The
results of the multivariate logistic analysis
also support this conclusion. Although in
a model including all type 2 diabetes risk
factors, FPG was a strong predictor of
type 2 diabetes risk in both studies, after
inclusion of 1-h plasma glucose in the lo-
gistic model, FPG no longer was a signif-
icant predictor of type 2 diabetes risk.
This observation suggests that the future
type 2 diabetes risk associated with in-
creased FPG is due primarily to its corre-
lation with the 1-h plasma glucose
concentration. These results are consis-
tent with previous studies reporting that
the 1-h plasma glucose concentration is a
strong predictor of type 2 diabetes risk,
independent of FPG and 2-h plasma glu-
coseconcentrations,andisastrongerpre-
dictor than measures taken during the
fasting state, e.g., FPG and A1C (6).
Wehypothesizethatthestrongcorre-
lation between insulin resistance in skel-
etal muscle and liver (16) is responsible,
in part, for the association between in-
creased postload hyperglycemia and ele-
vated FPG concentration. Indeed, the 1-h
plasma glucose concentration correlated
well with the FPG concentration (r 
0.37, P  0.0001).
Progressive -cell failure is the prin-
cipal factor responsible for the develop-
ment and progression of type 2 diabetes
(17). In previous studies, we have shown
that -cell failure develops at 2-h plasma
glucose concentrations well within the
normal range and that the severity of
-cellfailureisinverselyrelatedtothe2-h
plasma glucose concentration (24). For
example, subjects with a 2-h plasma glu-
cose concentration between 120 and 139
mg/dl have an 40–50% decrease in
-cell function compared with subjects
with a 2-h plasma glucose concentration
100 mg/dl. This range of postload hy-
perglycemia is comparable to that of sub-
jects studied in the present study. The
decrease in -cell function associated
with the increase in postload hyperglyce-
mia in this range would be expected to
contribute to the increased diabetes inci-
dence associated with the rise in postload
hyperglycemia.
The second important ﬁnding of this
study is that the rise in postload glycemia
in the range considered to be normal (2-h
plasmaglucose140mg/dl)isassociated
with a signiﬁcant increase in the inci-
dence of type 2 diabetes (Fig. 1, Table 3).
Thisincreaseddiabetesincidencewasob-
served both in subjects with NGT and
IFG. When postload glycemia is evalu-
ated using the 1-h plasma glucose con-
centration, the increase in incidence of
type 2 diabetes becomes evident at a 1-h
plasma glucose level of 125 mg/dl and in-
creases markedly as the 1-h plasma glu-
cose concentration exceeds 150 mg/dl,
independent of the FPG concentration
(Fig. 1). The marked increase in the inci-
dence of type 2 diabetes associated with
anincreasein1-hplasmaglucoseconcen-
tration 150 mg/dl is consistent with
previous studies in which a 1-h plasma
glucoseof155mg/dlidentiﬁedsubjectsat
high risk for future type 2 diabetes (6,7).
Previous epidemiological studies
have reported that, in absolute numbers,
25–40% of subjects who develop type
2 diabetes have a 2-h plasma glucose
140 mg/dl at baseline (2–4,8). Our re-
sults are consistent with these observa-
tions and extend them by demonstrating
thatthedevelopmentoftype2diabetesin
thisgroupconsideredtohavenormalglu-
cose tolerance is related to the increase in
postload glycemia.
The third important ﬁnding of this
study is that the 1-h plasma glucose con-
centration is a better measure for future
type 2 diabetes risk than the 2-h plasma
glucose concentration. Subjects with a
2-h plasma glucose 140 mg/dl and FPG
100 mg/dl, who according to the ADA
criteria (1) have NGT, could be stratiﬁed
into three risk groups for future develop-
mentoftype2diabetesbasedontheir1-h
plasma glucose concentration, and sub-
jects with a 1-h plasma glucose 155
mg/dl had a 13.1-fold increased odds ra-
tio (OR) for type 2 diabetes. Thus, this
group of subjects with “normal glucose
tolerance” has a risk for future type 2 di-
abetescomparabletothatofsubjectswith
IFG and IGT and should be considered to
have “glucose intolerance.” IFG and IGT
categories were introduced to represent
an intermediate stage in the transition
from NGT to type 2 diabetes and identify
subjects with increased risk for future
type 2 diabetes (1). The results of the
present study highlight the need either to
revise the current ADA cut points for de-
ﬁning glucose intolerance or to change
the criteria for NGT.
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